MetaCap

Climb Bio (CLYM) vs Geron (GERN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Climb Bio (CLYM) has outperformed Geron (GERN) over the past year, gaining 440.6% versus a loss of 22.3%. Over five years, CLYM leads with a -33.2% price change compared with -40.8% for GERN. Geron is the larger company by market cap ($560.9 million vs $539.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLYM+440.59%GERN-22.26%
+998%+464%-71%
Nov 21, 20251 yearNov 20, 2026
CLYM-48.46%GERN-43.46%
+232%+61%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLYM versus GERN key metrics
MetricCLYMGERN
Share price$9.19$0.8707
Market cap$539.80M$560.94M
1-day change-0.97%-4.63%
YTD return+129.75%-34.04%
1-year return+440.59%-22.26%
5-year return-33.21%-40.77%
Forward P/E—9.67
EPS (TTM)$-0.81$-0.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-59.85M$-83.50M
52-week high$18.33$2.01
52-week low$1.64$0.84
Distance from 52-week high-49.86%-56.68%
Analyst consensusstrong_buybuy
Avg. price target upside+209.03%+301.98%
Average volume1.38M13.05M
Shares outstanding58.74M644.24M
Employees28258
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CLYM has outperformed GERN by 462.8 percentage points over the past year.

About Climb Bio

CLYM stock →

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About Geron

GERN stock →

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.

Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees

CLYM vs GERN FAQ

Which is bigger, Climb Bio or Geron?

Geron (GERN) is larger, with a market capitalization of $560.94M compared with $539.80M for Climb Bio (CLYM).

Which stock has performed better over the past year, CLYM or GERN?

CLYM returned +440.59% over the past 12 months, compared with -22.26% for GERN (price return, excluding dividends). Past performance does not predict future results.

Are Climb Bio and Geron in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons